Scholars Central

Review articlePublished 2014

The Three-Level Approach: A Framework for Ensuring Medicines Quality in Limited-Resource Countries

Authors: Victor S Pribluda, Adrian Barojas, Veerle Coignez, Sanford Bradby, Yanga Dijiba, Latifa El-Hadri, Mustapha Hajjou, Laura Krech, Souly Phanouvong, Karim Smine, Kennedy Chibwe, Patrick H Lukulay, Lawrence Evans III

Pharmaceutical Regulatory Affairs: Open Access

Volume 3 · Issue 1 · Pages 1–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Regulators from countries at all levels of income struggle to protect the public from the dangers of poor-quality (counterfeit and substandard) medicines. In particular countries with limited resources are at higher risk because of weak regulations, insufficient personnel, or laboratories with poor infrastructure and a lack of equipment required to perform quality control analysis. A systematic approach is needed to address these gaps. A stepwise process was used to design medicine quality monitoring programs in numerous countries in Africa, South America, and Southeast Asia. The experience gained in these countries resulted in the development of the Three-level Approach for performing quality control of medicines throughout the supply chain. The approach consists of three successive, complementary, and increasingly complex levels of analysis: The first level includes visual and physical inspection to assess package and insert conditions and information as well as the physical characteristics of the actual medicines. The second level consists of rapid analytical tests that assess a limited number of quality attributes and can easily be performed in the field by trained personnel. The third level involves quality control testing according to the product’s registration specifications and is performed in an appropriate laboratory setting by experienced and trained analysts. The Three-level Approach offers regulators in limited resource countries, a cost-effective high-throughput methodology for quality monitoring that produces valid and trustworthy results. The approach strengthens medicines quality assurance systems by allowing better regulation of the pharmaceutical market, which ultimately reduces the prevalence of poor-quality medicines.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Victor S Pribluda”
  • BylineArticles whose byline prints “Adrian Barojas”
  • BylineArticles whose byline prints “Veerle Coignez”
  • BylineArticles whose byline prints “Sanford Bradby”
  • BylineArticles whose byline prints “Yanga Dijiba”
  • BylineArticles whose byline prints “Latifa El-Hadri”
  • BylineArticles whose byline prints “Mustapha Hajjou”
  • BylineArticles whose byline prints “Laura Krech”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels